Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$56.68 USD
+0.97 (1.74%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $56.69 +0.01 (0.02%) 7:08 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Company Summary
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.
Company Summary
General Information
Cytokinetics, Incorporated
350 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-624-3000
Fax: 650-624-3010
Web: http://www.cytokinetics.com
Email: investor@cytokinetics.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 9/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -1.26 |
Current Year EPS Consensus Estimate | -5.15 |
Estimated Long-Term EPS Growth Rate | 18.70 |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 55.71 |
52 Week High | 110.25 |
52 Week Low | 26.55 |
Beta | 0.77 |
20 Day Moving Average | 1,308,447.38 |
Target Price Consensus | 83.12 |
4 Week | -0.39 |
12 Week | -1.05 |
YTD | -33.27 |
4 Week | -3.83 |
12 Week | -3.05 |
YTD | -44.16 |
Shares Outstanding (millions) | 117.66 |
Market Capitalization (millions) | 6,554.81 |
Short Ratio | NA |
Last Split Date | 6/25/2013 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 2.24% |
vs. Previous Quarter | 1.50% |
vs. Previous Year | -71.28% |
vs. Previous Quarter | -70.18% |
Price/Book | 53.81 |
Price/Cash Flow | NA |
Price / Sales | 2,091.52 |
9/30/24 | NA |
6/30/24 | NA |
3/31/24 | NA |
9/30/24 | Pending Next EPS Report |
6/30/24 | -55.97 |
3/31/24 | -67.32 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 10.39 |
3/31/24 | 7.19 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 10.39 |
3/31/24 | 7.19 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -17,398.82 |
3/31/24 | -14,141.74 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -17,398.82 |
3/31/24 | -14,141.74 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -17,398.82 |
3/31/24 | -14,141.74 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 1.04 |
3/31/24 | -3.79 |
9/30/24 | NA |
6/30/24 | NA |
3/31/24 | NA |
9/30/24 | Pending Next EPS Report |
6/30/24 | 5.93 |
3/31/24 | NA |
9/30/24 | Pending Next EPS Report |
6/30/24 | 85.57 |
3/31/24 | NA |